We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Avacta Group Plc | LSE:AVCT | London | Ordinary Share | GB00BYYW9G87 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.30 | -0.66% | 45.00 | 44.50 | 45.50 | 45.25 | 44.25 | 45.25 | 2,905,504 | 16:28:25 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 10.06M | -39.19M | -0.1382 | -3.26 | 127.63M |
TIDMAVCT
Avacta Group PLC
05 May 2017
5 May 2017
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Avacta to Present at the Hardman Private Investor Forum
Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and research reagents, is pleased to announce that its Chief Executive, Alastair Smith, will be presenting at the Hardman Private Investor Forum on Tuesday 9(th) May in London at the University of Liverpool, 33 Finsbury Square, EC2A 1AG.
The evening event, which begins with registration at 17:30, provides an opportunity for investors to hear about the Company's Affimer(R) technology, its development plans and to discuss these with Alastair, Philippe Cotrel, the Company's Chief Commercial Officer, and with Dr Trevor Nicholls, Chairman of the Board.
ENDS
NOTES
For further information from Avacta Group plc, please contact:
Avacta Group plc Tel: +44 (0) Alastair Smith, Chief Executive 844 414 0452 Officer www.avacta.com Tony Gardiner, Chief Financial Officer finnCap Ltd Tel: +44 (0) Geoff Nash / Giles Rolls - Nominated 207 220 0500 Adviser www.finncap.com Tim Redfern / Alice Lane - Corporate Broking Tel: +44 (0) WG Partners 203 705 9318 Nigel Birks / Nigel Barnes Tel: +44 (0) David Wilson / Claes Spang 203 705 9217 www.wgpartners.co.uk Zyme Communications (Trade and Tel: +44 (0)7787 Regional Media) 502 947 Katie Odgaard katie.odgaard@zymecommunications.com FTI Consulting (Financial Media Tel: +44 (0) and IR) 203 727 1000 Simon Conway / Natalie Garland-Collins avacta@fticonsulting.com
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Affimer technology has been designed to address many of the negative performance issues of antibodies, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFEEEIISIID
(END) Dow Jones Newswires
May 05, 2017 02:01 ET (06:01 GMT)
1 Year Avacta Chart |
1 Month Avacta Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions